Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 256

1.

Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.

Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, Dalbeth N.

Arthritis Rheum. 2012 Aug;64(8):2529-36. doi: 10.1002/art.34488.

2.

Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.

Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.

Clin Pharmacol Ther. 2011 Sep;90(3):392-8. doi: 10.1038/clpt.2011.113. Epub 2011 Jul 27.

PMID:
21796116
3.
4.

Relation between adverse events associated with allopurinol and renal function in patients with gout.

Vázquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R.

Ann Rheum Dis. 2001 Oct;60(10):981-3.

5.

Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.

Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, van de Laar MA, Brouwers JR.

Ann Rheum Dis. 2009 Jan;68(1):51-6. doi: 10.1136/ard.2007.083071. Epub 2008 Feb 4.

PMID:
18250112
6.

Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Ramasamy SN, Korb-Wells CS, Kannangara DR, Smith MW, Wang N, Roberts DM, Graham GG, Williams KM, Day RO.

Drug Saf. 2013 Oct;36(10):953-80. doi: 10.1007/s40264-013-0084-0. Review.

PMID:
23873481
7.

Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.

Chohan S.

J Rheumatol. 2011 Sep;38(9):1957-9. doi: 10.3899/jrheum.110092. Epub 2011 Jul 1.

PMID:
21724706
8.
9.

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.

Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

10.

Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.

Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.

Rheumatology (Oxford). 2012 Sep;51(9):1670-6. doi: 10.1093/rheumatology/kes091. Epub 2012 Apr 26.

11.

Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.

Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT.

Arthritis Rheum. 2011 Feb;63(2):412-21. doi: 10.1002/art.30119.

12.

As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.

Tausche AK, Christoph M, Forkmann M, Richter U, Kopprasch S, Bielitz C, Aringer M, Wunderlich C.

Rheumatol Int. 2014 Jan;34(1):101-9. doi: 10.1007/s00296-013-2857-2. Epub 2013 Sep 12.

PMID:
24026528
13.

[Fatal liver necrosis due to allopurinol].

Pereira S, Almeida J, Silva AO, Quintas M, Candeias O, Freitas F.

Acta Med Port. 1998 Dec;11(12):1141-4. Review. Portuguese.

14.

Does starting allopurinol prolong acute treated gout? A randomized clinical trial.

Hill EM, Sky K, Sit M, Collamer A, Higgs J.

J Clin Rheumatol. 2015 Apr;21(3):120-5. doi: 10.1097/RHU.0000000000000235.

PMID:
25807090
15.

Allopurinol hypersensitivity syndrome in patients with hematological malignancies: characteristics and clinical outcomes.

Min HK, Lee B, Kwok SK, Ju JH, Kim WU, Park YM, Park SH.

Korean J Intern Med. 2015 Jul;30(4):521-30. doi: 10.3904/kjim.2015.30.4.521. Epub 2015 Jun 29.

16.

Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.

Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P.

Postgrad Med. 2014 Mar;126(2):65-75. doi: 10.3810/pgm.2014.03.2741.

PMID:
24685969
17.

Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N.

N Engl J Med. 2005 Dec 8;353(23):2450-61.

18.

Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?

Lee HY, Ariyasinghe JT, Thirumoorthy T.

Singapore Med J. 2008 May;49(5):384-7.

19.

Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study.

Søltoft Larsen K, Pottegård A, Lindegaard HM, Hallas J.

PLoS One. 2016 Jan 11;11(1):e0146172. doi: 10.1371/journal.pone.0146172. eCollection 2016.

20.

An open-label, 6-month study of allopurinol safety in gout: The LASSO study.

Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, Baumgartner S.

Semin Arthritis Rheum. 2015 Oct;45(2):174-83. doi: 10.1016/j.semarthrit.2015.05.005. Epub 2015 May 21.

Items per page

Supplemental Content

Write to the Help Desk